Categories
Uncategorized

Milan, November 16, 2017. Home Healthcare Market worth 365 Billion USD by 2022. Rising incidence of chronic diseases, testing, screening and monitoring new technologies to drive market growth.

[et_pb_section bb_built=”1″ background_color=”#ffffff” _builder_version=”3.5″ background_image=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/green-triangle-pattern-grey-top-only.png” parallax=”on” animation_style=”slide” animation_direction=”left” animation_duration=”550ms” animation_intensity_slide=”5%” box_shadow_style=”preset3″ box_shadow_vertical=”23px” box_shadow_blur=”30px” box_shadow_spread=”-11px” box_shadow_color=”rgba(145,145,145,0.3)”][et_pb_row _builder_version=”3.0.92″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

According to a new market research report from MarketsandMarkets, the global home healthcare market is expected to reach USD 365 Billion by 2022 growing at a CAGR of 8.8 from 2017 to 2012. Testing, screening, and monitoring devices are expected to dominate the market due to emphasis on diseases prevention and technological advancements. “The Dianax mobile lab-on-a-chip device has been designed to bring diagnostics testing, screening and monitoring directly into patient homes and to patients wherever they may be. It empowers patients to take a more active role in their care.” says Pascal Pouligny, Chief Marketing Officer. “We are seeing a tectonic shift in healthcare infrastructure as we know it, powered by the smartphone revolution, and Dianax is at the cutting-edge of mobile diagnostic transformation. It is our belief that rapid detection combined with informed decision-making will optimize treatment and improve patient outcomes. Whether it be expediting the screening, diagnosis and management of chronic diseases such as diabetes or anemia or the next global outbreak of infectious disease, Dianax aims to provide fast, reliable and affordable diagnostics at the point of need – anywhere, anytime and for anyone.”

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

Categories
Uncategorized

Lyon, November 16, 2017. dianax among the TOP WINNERS of BIGBOOSTER camp in Lyon and QUALIFIED for the next round!

[et_pb_section fb_built=”1″ background_color=”#ffffff” _builder_version=”3.0.92″ background_image=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/green-triangle-pattern-grey-top-only.png” parallax=”on” animation_style=”slide” animation_direction=”left” animation_duration=”550ms” animation_intensity_slide=”5%” box_shadow_style=”preset3″ box_shadow_vertical=”23px” box_shadow_blur=”30px” box_shadow_spread=”-11px” box_shadow_color=”rgba(145,145,145,0.3)” global_module=”25744″][et_pb_row _builder_version=”3.0.92″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_image src=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/big-booster-2.png” _builder_version=”3.0.92″][/et_pb_image][et_pb_text _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

At the end of a 3-day intensive program combining tutorial on best practices, mentoring and individual coaching, dianax ‘s pitch was recognized by an expert jury among the best in class and is qualified for the next round that will take the top 20 startups to Boston or Shenzen! Go Team dianax!

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

Categories
Uncategorized

Milan, November 03, 2017. Europe POCT Market to reach almost USD 12 billion by 2024 – Emerging Microfluidic Lab-on-a-Chip Technology.

[et_pb_section bb_built=”1″ background_color=”#ffffff” _builder_version=”3.0.92″ background_image=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/green-triangle-pattern-grey-top-only.png” parallax=”on” animation_style=”slide” animation_direction=”left” animation_duration=”550ms” animation_intensity_slide=”5%” box_shadow_style=”preset3″ box_shadow_vertical=”23px” box_shadow_blur=”30px” box_shadow_spread=”-11px” box_shadow_color=”rgba(145,145,145,0.3)”][et_pb_row _builder_version=”3.0.92″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″][et_pb_text _builder_version=”3.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

dianax miniaturized microfluidics-based lab-on-a-chip will bring laboratory testing to the patient’s fingertips including HbA1c and CRP. According to Data Bridge Market Research, the Europe Point-of-Care Testing (POCT) devices market is expected to reach USD 11,682.54 billion by 2024 from USD 6,051.05 billion in 2016, at a CAGR of 8.6% in the forecast period 2017 to 2024. The major factors driving the growth of this market are the increasing incidence of chronic diseases, rising demand for self-testing point-of-care testing devices, decentralized laboratory testing, and technological advancements like microfluidic lab on a chip technology. These factors increase the demand for devices such as blood glucose meter, HBA1C, CRP… More info at http://databridgemarketresearch.com/news/product-launch/europe-poct-device-market/

[/et_pb_text][et_pb_image src=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/CHIP.jpg” _builder_version=”3.5″]
[/et_pb_image][/et_pb_column][/et_pb_row][/et_pb_section]

Categories
Uncategorized

Milan, November 02, 2017. dianax selected among the TOP 100 innovative early stage global companies to participate to BigBooster camp in Lyon from November 14th until November 16th.

[et_pb_section fb_built=”1″ background_color=”#ffffff” _builder_version=”3.0.92″ background_image=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/green-triangle-pattern-grey-top-only.png” parallax=”on” animation_style=”slide” animation_direction=”left” animation_duration=”550ms” animation_intensity_slide=”5%” box_shadow_style=”preset3″ box_shadow_vertical=”23px” box_shadow_blur=”30px” box_shadow_spread=”-11px” box_shadow_color=”rgba(145,145,145,0.3)” global_module=”25744″][et_pb_row _builder_version=”3.0.92″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_image src=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/big-booster.png” _builder_version=”3.0.92″][/et_pb_image][et_pb_text _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

Organized across the globe, from Lyon (FR) to Boston (MA, USA), passing through China, Middle East & Africa, BigBooster unique international non-profit acceleration program aims at empowering startups to cross borders, think global and go international, with the help of major mentors, coach, and startup experts of all backgrounds. The pitch contest at the end of this Booster camp will take the top 20 startups to Boston for the next round…

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

Categories
Uncategorized

Lausanne and Milan, October 11, 2017. dianax among the Top 10 startups to reach Tech Tour 2017 European Venture Contest Final…

[et_pb_section fb_built=”1″ background_color=”#ffffff” _builder_version=”3.0.92″ background_image=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/green-triangle-pattern-grey-top-only.png” parallax=”on” animation_style=”slide” animation_direction=”left” animation_duration=”550ms” animation_intensity_slide=”5%” box_shadow_style=”preset3″ box_shadow_vertical=”23px” box_shadow_blur=”30px” box_shadow_spread=”-11px” box_shadow_color=”rgba(145,145,145,0.3)” global_module=”25744″][et_pb_row _builder_version=”3.0.92″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_image src=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/european-venture.png” _builder_version=”3.0.92″][/et_pb_image][et_pb_text _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

dianax is among the top 10 Alpine region startup companies qualified for the 2017 final of the Tech Tour European Venture Contest (EVC). A total of 105 companies applied to the event, only 40 of them were invited to pitch in front of international investors and corporate executives and the top quartile (best 25%) companies are qualified for the EVC Final which will take place in Dusseldorf on 11 – 12 December 2017. “This is an important milestone for our Company,” says Andrea Zanella, CEO of dianax, “a great recognition of all the work accomplished and an appreciation of the high-value and tremendous market potential of our BioMEMS lab-on-a –chip technology.” Tech Tour is one of the largest investor-oriented communities in Europe connecting entrepreneurs, investors and corporate partners from across the world. Over 2000 high-tech companies apply and 750 investors take part in 25 leading tech events held each year.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

Categories
Uncategorized

Lausanne and Milan, September 22, 2017. dianax selected to present at the Alpine High-Tech Venture Forum 2017 in Lausanne.

[et_pb_section bb_built=”1″ background_color=”#ffffff” _builder_version=”3.0.92″ background_image=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/green-triangle-pattern-grey-top-only.png” parallax=”on” animation_style=”slide” animation_direction=”left” animation_duration=”550ms” animation_intensity_slide=”5%” box_shadow_style=”preset3″ box_shadow_vertical=”23px” box_shadow_blur=”30px” box_shadow_spread=”-11px” box_shadow_color=”rgba(145,145,145,0.3)”][et_pb_row _builder_version=”3.0.92″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″][et_pb_image src=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/alpine-high-tech.jpg” _builder_version=”3.5″]
[/et_pb_image][et_pb_text _builder_version=”3.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

Dianax is among the top 40 Alpine region companies selected to present at the Forum on 10 October in Lausanne. 104 companies applied and were reviewed by the Expert Jury over the past months. At the Alpine Venture Forum 2016 took part +50 Swiss and International investors, business angels and corporate representatives.

[/et_pb_text][et_pb_image src=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/european-venture.png” _builder_version=”3.5″]
[/et_pb_image][/et_pb_column][/et_pb_row][/et_pb_section]

Categories
Uncategorized

Milan, September 14, 2017. Point of Care Testing Market is projected to reach US$ 38 Billion Globally by 2022

[et_pb_section fb_built=”1″ background_color=”#ffffff” _builder_version=”3.0.92″ background_image=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/green-triangle-pattern-grey-top-only.png” parallax=”on” animation_style=”slide” animation_direction=”left” animation_duration=”550ms” animation_intensity_slide=”5%” box_shadow_style=”preset3″ box_shadow_vertical=”23px” box_shadow_blur=”30px” box_shadow_spread=”-11px” box_shadow_color=”rgba(145,145,145,0.3)” global_module=”25744″][et_pb_row _builder_version=”3.0.92″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

According to a very recent report from Reports Monitor (ReportsMonitor.com), Point of care (POC) technologies are rapidly becoming parts of the revolution of the healthcare landscape, with evolving high–tech innovations in healthcare, including smartphone apps, biosensors, lab–on–a chip, and wearable devices—all of which offer a closer connection to the patient. The dynamic of point of–care testing (POCT) is to bring testing closer to the patient and results conveniently and quickly to the provider to expedite diagnosis and subsequent treatment. POCT allows for faster clinical decisions in hospitals, physicians’ offices, ambulances, patient homes, and in the field. More info at http://www.tradecalls.org/2017-09-13-point-care-testing-market-projected

[/et_pb_text][et_pb_image src=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/graph-2.png” _builder_version=”3.0.92″][/et_pb_image][/et_pb_column][/et_pb_row][/et_pb_section]

Categories
Uncategorized

Milan, July 27, 2017. Are Doctors Prescribing Antibiotics Too Often for Sinus Infections? (Source Newsroom: University of Georgia-26-Jul-2017)

[et_pb_section fb_built=”1″ background_color=”#ffffff” _builder_version=”3.0.92″ background_image=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/green-triangle-pattern-grey-top-only.png” parallax=”on” animation_style=”slide” animation_direction=”left” animation_duration=”550ms” animation_intensity_slide=”5%” box_shadow_style=”preset3″ box_shadow_vertical=”23px” box_shadow_blur=”30px” box_shadow_spread=”-11px” box_shadow_color=”rgba(145,145,145,0.3)” global_module=”25744″][et_pb_row custom_padding=”27px|0px|2px|0px” _builder_version=”3.0.92″][et_pb_column type=”4_4″ _builder_version=”3.0.92″ parallax=”off” parallax_method=”on”][et_pb_image src=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/universoty-of-georgia.png” _builder_version=”3.0.92″][/et_pb_image][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”3.0.92″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

C-reactive protein (CRP) point of care tests may help reduce unnecessary antibiotic use. Sinus infections are one of the most common reasons patients walk out of the doctor’s office with an antibiotic prescription in hand. The problem is that bacteria causes only about one-third of sinus infections, which means most patients are inappropriately receiving antibiotics. Unnecessary antibiotic use is one of the leading contributors to antibiotic-resistant infections, according to the Centers for Disease Control and Prevention. To curb unnecessary antibiotic prescribing, physician and University of Georgia researcher Mark Ebell developed a clinical decision rule for diagnosing sinus infections, or acute rhinosinusitis. In a study appearing in the Annals of Family Medicine, Ebell presents a series of simple clinical rules that integrate patient symptoms and simple lab tests (CRP test) to accurately detect acute bacterial rhinosinusitis. CRP tests detect inflammation in the body, which can indicate an infection. This is an important component of the point score, Ebell said, though CRP testing is currently unavailable in most primary care settings in the U.S. “That’s one of the issues we wanted to call attention to,” he said. “This is a test that’s widely used by doctors in Europe, the U.K. and Australia, and has been shown to decrease inappropriate antibiotic use.” Ebell’s next plan is to perform a randomized clinical trial to test the effectiveness of the point score system, including the use of a CRP test, in clinical practice. “We need to give physicians better tools to support their decision-making, and that can include clinical decision rules and point of care tests like CRP,” Ebell said. “The study, “Proposed Clinical Decision Rules to Diagnose Acute Rhinosinusitis Among Adults in Primary Care,” is available online at http://www.annfammed.org/content/15/4/347.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]

Categories
Uncategorized

Milan, July 21, 2017. IBM predicts lab-on-a-chip tech will change our lives …

[et_pb_section fb_built=”1″ background_color=”#ffffff” _builder_version=”3.0.92″ parallax=”on” animation_style=”slide” animation_direction=”left” animation_duration=”550ms” animation_intensity_slide=”5%” box_shadow_style=”preset3″ box_shadow_vertical=”23px” box_shadow_blur=”30px” box_shadow_spread=”-11px” box_shadow_color=”rgba(145,145,145,0.3)” global_module=”25744″ background_image=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/green-triangle-pattern-grey-top-only.png”][et_pb_row _builder_version=”3.0.92″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_text _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

According to IBM’s latest predictions, medical device labs-on-a-chip will serve as health detectives for tracing disease at the nanoscale. In the next five years, new medical device labs-on-a-chip will serve as nanotechnology health detectives – tracing invisible clues in our bodily fluids and letting us know immediately if we have reason to see a doctor. The goal is to shrink down to a single silicon chip all of the processes necessary to analyze a disease that would normally be carried out in a full-scale biochemistry lab. The lab-on-a-chip technology could ultimately be packaged in a convenient handheld medical device to allow people to quickly and regularly measure the presence of biomarkers found in small amounts of bodily fluids, sending this information securely streaming into the cloud from the convenience of their home….  More at http://www.medicalplasticsnews.com/news/technology/ibm-predicts-lab-on-a-chip-tech-will-change-our-lives/

[/et_pb_text][/et_pb_column][/et_pb_row][et_pb_row _builder_version=”3.0.92″ custom_padding=”27px|0px|2px|0px”][et_pb_column type=”4_4″ _builder_version=”3.0.92″ parallax=”off” parallax_method=”on”][et_pb_image src=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/milan.jpg” _builder_version=”3.0.92″][/et_pb_image][/et_pb_column][/et_pb_row][/et_pb_section]

Categories
Uncategorized

Milan, July ???. ADA Acknowledges Dental Team’s Role in Diabetes Epidemic…

[et_pb_section fb_built=”1″ background_color=”#ffffff” _builder_version=”3.0.92″ parallax=”on” animation_style=”slide” animation_direction=”left” animation_duration=”550ms” animation_intensity_slide=”5%” box_shadow_style=”preset3″ box_shadow_vertical=”23px” box_shadow_blur=”30px” box_shadow_spread=”-11px” box_shadow_color=”rgba(145,145,145,0.3)” global_module=”25744″][et_pb_row _builder_version=”3.0.92″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.0.47″ parallax=”off” parallax_method=”on”][et_pb_image src=”http://www.helentestsite.co.uk/wp-content/uploads/2018/01/diabetes-periodontis.png” _builder_version=”3.0.92″][/et_pb_image][et_pb_text _builder_version=”3.0.47″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]

Type 2 diabetes has escalated to epidemic and financially catastrophic proportions, and is expected to affect one in three US adults by 2050. We already have more than 29 million diabetics in this country today; 28% remain undiagnosed. With the well-established connection between diabetes and periodontal disease and the greater likelihood that patients will see a dentist than a physician, there is a clear opportunity for dental teams to assist in this health crisis. In-office diabetes screening provides the dental team with critical health information needed to successfully address patients’ oral health while ensuring patients are referred for the medical care they may be unaware they need. The American Diabetes Association (ADA) and Code Maintenance Committee (CMC) announced the addition of a new 2018 code that will report the in-office measure of hemoglobin A1c.

[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]